Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 333 participants.
Also called NCT03624881
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 333 participants
- Sponsor
- Registry
-
NCT03624881
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03624881. Allocation not applicable; no masking; primary purpose treatment. Start 2018-09-04 (actual); primary completion 2021-06-28 (actual). Results posted on 2022-09-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU)
- Condition
- Paroxysmal Atrial Fibrillation
- Intervention (Device)
- Catheter ablation with EPU
- Lead sponsor
- Biosense Webster, Inc.
Record details
- Record id
cardio:ct-nct03624881- Content hash
ceecf1566c65a59d301fb036f9cf09ebefe7a7741ef63c82ce7fac1990212c42